The FDA granted fast track status to VectorY’s VTx-002, an antibody gene therapy targeting TDP-43 protein aggregates in ALS.
First MIRACLE trial unblinding expected Q1 2026; Global trial now spans nine countries – Investigator-Initiated (IIT) funded ...
The FDA has granted fast track designation to a vectorized antibody that targets RNA-binding proteins characteristic of ...
Phase 3 SELVA study evaluating QTORIN™ rapamycin 3.9% anhydrous gel (QTORIN™ rapamycin) for microcystic lymphatic ...
Sanofi’s chlamydia vaccine candidate was designed to protect against primary genital tract infection and reinfection by the bacterium Chlamydia trachomatis. The Food and Drug Administration (FDA) has ...
France will introduce in 2026 a “fast-track” pathway aimed at accelerating the authorisation of certain mono-national clinical trials. Reserved in particular for early-phase studies, serious diseases ...
Entrada Therapeutics plans to initiate ELEVATE-44-201 trial for ENTR-601-44 in Duchenne muscular dystrophy by Q2 2025. Entrada Therapeutics, Inc. announced that it has received regulatory ...
Zentalis reports updated DENALI trial results for azenosertib in platinum-resistant ovarian cancer, showing 6.3 months median duration of response. Updated median duration of response (mDOR) of 6.3 ...
A research team from China has introduced the first standardized framework for evaluating the clinical applicability of medical AI systems, with their findings published in npj Digital Medicine, a ...
A new academic track at the Warren Alpert Medical School will help biomedical faculty be recognized for their clinical expertise. Before the new clinician scholar track was approved, Warren Alpert ...
Clinical Trials Arena on MSN
UK introduces clinical trial regulatory reforms to enhance research appeal
The new rules introduce a fast-track notification route, enabling quicker starts for lower-risk trials and maintaining safety ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback